Quick Answer
Allogene Therapeutics, Inc. reported Operating Income Loss of -$209.32 million for the year ending 2025.
- Allogene Therapeutics, Inc. showed an increase of +23.4% in Operating Income Loss from 2024 to 2025.
- This data is from Allogene Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Allogene Therapeutics, Inc.'s Operating Income Loss has declined by 10,465,650.0%.
- Historical annual values: Fiscal year 2025: -$209.32 million | Fiscal year 2024: -$273.20 million | Fiscal year 2023: -$327.74 million | Fiscal year 2022: -$335.54 million | Fiscal year 2021: -$180.19 million | Fiscal year 2020: -$258.24 million | Fiscal year 2019: -$202.01 million | Fiscal year 2018: -$192.84 million | Fiscal year 2017: -$2.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: